Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 16th October 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Pirbright partners on projects to develop PRRS vaccines
PRRSV is responsible for one of the most damaging diseases to the global pig industry.
Disease costs pig farmers in Europe an estimated €1.5 billion a year. 

The Pirbright Institute has announced that it is joining forces with ECO Animal Health and The Vaccine Group (TVG) in two projects to develop new vaccines for porcine respiratory and reproductive syndrome virus (PRRSC).

PRRSV (type-1 and type -2) is responsible for one of the most damaging diseases to the global pig industry, costing pig farmers in Europe an estimated € 1.5 billion a year and those in the US some $600 million.

The first project will see Pirbirght test two vaccine candidates that use TVG's vaccine technology to assess their effectiveness at tackling PRRSV in pigs. The vaccines are created by using TVG technology to insert non-infectious conserved PRRSV genes supplied by Pirbright into a benign herpesvirus, which then stimulates the immune system when delivered into animals.

Professor Simon Graham, group leader of PRRS Immunology at The Pirbright Institute said, said: “This is an exciting project that takes a novel approach to addressing the urgent requirement for improved vaccines to combat the global spread of PRRSV.”

Associate Professor Dr Michael Jarvis, TVG founder and chief scientific officer,  said: “This is an exciting opportunity that brings together critical basic science and translational expertise towards addressing this major infectious disease in pigs. As PRRSV is a member of the Nidovirus group of viruses, a group that also contains SARS-CoV-2, what we learn from development of a PRRSV vaccine may also help inform our development of a vaccine against SARS-CoV-2.”

In the second project, Pirbright will work with ECO to develop a significantly improved killed vaccine over 18 months. The team will generate modified PRRSV strains and then inactivate them to create vaccine candidates.

Dr Hafid Benchaoui, head of global R&D at the ECO Animal Health Group added: “ECO Animal Health recognises the significant, ongoing challenge that PRRSV poses for pig producers all over the world. This collaboration with The Pirbright Institute and The Vaccine Group leverages the deep scientific expertise of The Pirbright Institute and The Vaccine Group’s novel herpesvirus vector technology in an exciting new approach to PRRSV vaccination.”

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
BSAVA publishes fifth Manual of Canine and Feline Neurology

The BSAVA has published the fifth edition of its BSAVA Manual of Canine and Feline Neurology.

The new edition has been reviewed and updated, including new developments in diagnostics, therapeutic approaches and clinical decision-making. It is structured to support clinicians through diagnosis, treatment and long-term management.

The guide features five new chapters covering acute myelopathies, chronic myelopathies, emergency protocols, neurotoxicology and neuro-oncology.

It also includes over 100 videos, including demonstrations of neurological examinations, clinical presentations and diagnostic procedures.

Nicola Lloyd, publishing manager, said: "Whether you're a general practitioner seeking practical guidance, or a specialist aiming to refine your expertise, this edition remains an indispensable reference for anyone involved in the care of neurologically compromised dogs and cats."